We are live on ! Find out more

Kiniksa Pharmaceuticals

KNSA

Market cap $5.99B

76.76 USD

+0.49

0.64%

At close Updated Sep 14, 1:44 PM EDT

1 day

0.64%

5 days

0.67%

1 month

0.01%

3 months

46.66%

6 months

65.08%

Year to date

82.72%

1 year

109.96%

5 years

532.29%

10 years

294.25%

About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Employees: 366

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 68%

Neutral 24%

Negative 8%

Investors Business Daily

Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat

Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers.

Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time.

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

Investors Business Daily

Three Biotech Stocks Stick Out With Their Stellar Charts

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

Three Biotech Stocks Stick Out With Their Stellar Charts

Investors Business Daily

Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan

Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining in 2030. But the company has a plan.

Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan

Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3

Kiniksa Pharmaceuticals International NASDAQ: KNSA said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of follow-on candidate KPL-387.

Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time.

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

Zacks Investment Research

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook

KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook

Zacks Investment Research

Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?

Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights

Kiniksa Pharmaceuticals International NASDAQ: KNSA reported second-quarter ARCALYST revenue of $243.6 million, up 55% from a year earlier and more than $29 million from the first quarter, as the company cited continued expansion in both new and repeat prescribers for the recurrent pericarditis treatment.

Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™